

RHINOMED

CAPITAL RAISING PRESENTATION - SEPTEMBER 2019

ASX:RNO
OTCQB:RHNMF

Not for release to US wire services or distribution in the United States

IMPORTANT NOTICE

IMPORTANT NOTICE AND DISCLAIMER

You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any modifications to them. The information in this document has been prepared in good faith by Rhinomed Limited ACN 107 903 159 (Rhinomed). This document is intended as a guide only and does not provide, and does not purport to contain, all of the information that the recipient may require for the purpose of evaluating any offer to subscribe for shares in Rhinomed (Offer). Rhinomed has prepared this document based on information available to it to date. No representation or warranty, express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this document or any other information provided by Rhinomed, its respective affiliates or related bodies corporate (as that term is defined in the Corporations Act 2001 (Cth) (Corporations Act) or their respective officers, employees, directors, partners, representatives, agents, consultants or advisers (each a Limited Party and together, the Limited Parties) or any other person otherwise provides to you. To the maximum extent permitted by law, neither Rhinomed, Bell Potter Securities Limited (Lead Manager), their respective affiliates or related bodies corporate accepts any liability including, without limitation, any liability arising from fault, negligence or omission on the part of any person, for any loss, costs or damage arising from the use of this document or its contents or otherwise arising in connection with it. This includes for any indirect, incidental, consequential, special or economic loss or damage (including without limitation, any loss of profit or anticipated profit, fines or penalties, loss of business, or anticipated savings, loss of use, business interruption or loss of goodwill, bargain or opportunities).

The Lead Manager, its affiliates and related bodies corporate have not authorised, approved, endorsed or caused the issue of this document nor any of its contents, and accept no responsibility or liability for the contents or use of this document or otherwise arising in connection with it and make no recommendations, representations or warranties concerning the Offer or any offering of securities, or whether or not any person should participate in the Offer or make a commitment to participate in any way in the Offer. By accepting this document, you acknowledge and agree that there is no statement in this document which has been made by or is based on any statement made by the Lead Manager and that the Lead Manager is relying on the truth and accuracy of the representations and warranties given by you. This document is provided to you as an Australian investor who is a professional investor or sophisticated investor (as defined in the Corporations Act), to whom a prospectus is not required to be given under Chapter 6D of the Corporations Act. In accepting this document, you warrant that you are such an investor. If you are located in any other jurisdiction, you warrant that you are a person to whom securities can lawfully be issued under all applicable laws, without the need for any registration, lodgement or other formality. Except as described below, this document must not be distributed into the United States, Canada or Japan or distributed to any United States persons. If you are not such a person, please do not read this document. Please return it immediately to Rhinomed and destroy or delete any copies.

This document has not been lodged with ASIC, or otherwise.

Not an offer

This document, and the information contained in it, is provided for information purposes only and is not an offer or invitation or recommendation to subscribe for, acquire or buy any securities in Rhinomed, including the New Shares, or any other financial products or securities in any jurisdiction. To avoid any doubt, this document is not a prospectus, product disclosure statement or other disclosure or offer document under the Corporations Act or other offering document under any other Australian law, or any law of any other jurisdiction. Accordingly, this document does not contain all the information that would be required to be included in a prospectus, product disclosure statement or other disclosure or offer document prepared in accordance with the requirements of the Corporations Act and has not been lodged with ASIC or any other financial services or securities regulator. This document does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933, as amended (US Securities Act) or the securities laws of any US state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, in the United States or to any person in the United States unless they have been registered under the US Securities Act (which Rhinomed has no obligation to do or procure) or are offered and sold in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and any other applicable US state securities laws.

The distribution of this document (including an electronic copy) in the United States and other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Persons who come into possession of this document who are not in Australia should observe any such restrictions. Any non-compliance with such restrictions may contravene applicable securities laws. Please refer to the section of this document headed "International Offer Restrictions" in Appendix B of this document for more information.

Summary information

This document contains summary information about Rhinomed and its activities which is current as at the date of this document, unless otherwise indicated. The information in this document remains subject to change without notice, and Rhinomed is not responsible for updating, nor does it undertake to update, it. This presentation should be read in conjunction with Rhinomed's periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at <https://www.rhinomed.global/investor-information/> or www.asx.com.au.

Risk Factors

An investment in Rhinomed securities is subject to known and unknown risks, a number of which are beyond the control of Rhinomed. Rhinomed does not guarantee any particular rate of return or the performance, nor does it guarantee the repayment of capital from Rhinomed or any particular tax treatment. Prospective investors should have regard to the risk factors relating to Rhinomed's business and an investment in its securities as set forth in the "Key Risks" section of this document in Appendix C. When making their investment decision prospective investors should make their own enquiries and investigations regarding all information in this document, including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Rhinomed and the impact that different future outcomes may have on Rhinomed.

The information contained in this document has been prepared in good faith by Rhinomed however no guarantee representation or warranty expressed or implied is or will be made by any person (including Rhinomed and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, Rhinomed and its affiliates and their directors, officers employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by Rhinomed or any of its affiliates for updating any information in this document or to inform any recipient of any new or more accurate information or any errors or mis-descriptions of which Rhinomed and any of its affiliates or advisers may become aware.

Forward Looking statements

This document contains certain forward-looking statements, relating to Rhinomed Limited's (Rhinomed) business which can be identified by the use of forward looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of the company's technologies and products.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales.

In particular, managements expectations regarding the approval and commercialization of the technology could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and business prospects.

Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Rhinomed is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Not Financial Product Advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in Rhinomed is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

Information in this Document is Confidential

This document and the information contained within it are strictly confidential and are intended for the exclusive benefit of the persons to whom it is given. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Rhinomed. By receiving this document, you agree to keep the information confidential, not to disclose any of the information contained in this document to any other person and not to copy, use, publish, record or reproduce the information in this document without the prior written consent of Rhinomed, which may be withheld in its absolute discretion.

Acceptance

By attending an investor presentation or briefing, or accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as set.

Copyright

The information contained within this document is copyright by Rhinomed 2019.


RHINOMED LIMITED

TOPLINE SUMMARY

- Rhinomed is a commercial stage nasal technology and drug delivery company:
 - Targeting large addressable markets in Sport, Sleep, Nausea, Allergy/Congestion, Pain and Anxiety
 - Products stocked in 13,000 stores globally – Walgreens, CVS, Boots and online with Amazon
- Rhinomed is experiencing rapid growth globally as consumer awareness grows:
 - Revenues growing at 60%+ FY19 to FY20 – exceeding \$5m
 - Products for sale increasing from three to eight in 2020
 - Committed stores expected to grow from 13k to circa 30k by end of 2021
 - Entering the fast growing global CBD market in 2020
 - Potential for licensing deals for drug delivery
- Significant operating leverage as revenues grows:
 - 70%+ gross margins
 - Low fixed cost base circa \$5m pa.
 - R&D costs sunk and regulatory approvals already granted
- Company has raised \$6.0m via a Placement. Funds raised to support significant growth in sales, store rollout and working capital

RHINOMED

CORPORATE OVERVIEW



Key Metrics

Market Cap	~AU\$34m
Current Stock price	A\$0.24
Shares on issue	141m
Top 20 Investors	68%

Board and Management


Mr Ron Dewhurst	Chairman
Mr Michael Johnson	CEO and Managing Director
Mr Brent Scrimshaw	Non Executive Director
Dr Eric Knight	Non Executive Director
Mr Sean Slattery	CFO

Top Investors

Mr Whitney George (US)	25%
Dr John McBain (Aust)	9%
Mr Paul Stephens (US)	6%
Mr Ron Dewhurst (Aust)	6%

RHINOMED LIMITED

DELIVERING A GLOBAL STRATEGY BUILT UPON FOUR PILLARS





DELIVERED 50% YEAR ON YEAR REVENUE GROWTH

ONGOING REVENUE GROWTH OF AT LEAST 50%



- Revenue growth to accelerate in FY20 and beyond driven by organic growth in current products, new product launches and significant store growth.



PRODUCTS, DISTRIBUTION AND LICENSING

BUILDING CATEGORY LEADING BRANDS DELIVERING SALES AND PRODUCT SUCCESS



2014



2016



1H 2019




2H 2019

TURBINE SPORT BREATHING TECHNOLOGY

FIRST PRODUCT SUCCESSFULLY COMMERCIALISED


- Niche position in global sport, yoga, aerobic exercise markets
- Online Distribution and select US stores
- 70% Gross Margins
- Adopted by athletes in cycling, aerobic activity – used in Tour de France, Rio Olympics, etc.
- Class 1 registration with US FDA, CE Mark, Australian TGA, Canada Health and Taiwanese FDA



MUTE - FASTEST GROWING BRAND IN US NASAL STRIP MARKET

CONSUMER HEALTH PRODUCT FOR GLOBAL SLEEP MARKET

- Now in 13,000+ stores globally
- 11,000 in USA, 2,000 ROW
- 70% Gross Margins
- Delivered 95% of FY19 revenues
- Class 1 registration with US FDA, CE Mark, Australian TGA, Canada Health and Taiwanese FDA
- Companion therapy for Obstructive Sleep Apnea market – CPAP and Oral Advancement Therapies



PRONTO SLEEP – LAUNCHED JULY 2019

DRIVING GROWTH IN GLOBAL OTC SLEEP CATEGORY



- On shelf in ~1,000 Walgreens stores from July 2019
- Seeking to replicate Mute distribution of 13,000 stores globally and online
- 70% Gross margins
- FDA, CE Mark and TGA Class 1 registration May 2019
- Proprietary essential oil formulation to aid with sleep
- Unique rechargeable pod delivering up to 10 nights of better sleep
- Strengthening Rhinomed presence in global Sleep category



PRONTO CLEAR – RETAIL LAUNCH DECEMBER 2019

BRINGING INNOVATION TO GLOBAL DECONGESTION MARKET



- Retail launch late 2019
- Seeking to replicate Mute distribution of 13,000 stores globally 2020/21
- 70% Gross margins
- FDA, CE Mark and TGA Class 1 registration May 2019
- Proprietary nasal decongestion essential oil formulation
- Unique rechargeable pod delivering up to 10 nights of nasal relief
- Growing Rhinomed's presence in global nasal congestion market




NEW PRODUCT ROLL OUT IN 2020

TARGETING THE GLOBAL CBD CONSUMER HEALTH MARKET

New Product range


- Leveraging Rhinomed platform
- Targeting clear unmet needs in the global CBD consumer health market




Targeting an \$18bn* opportunity

- Leveraging Rhinomed’s 13,000 + existing retail network
 - Via Columbia Care in USA
 - Via Rhinomed’s retail network in ROW

Figure 13: CBD sales by channel \$Bn



Source: Canaccord Genuity estimates



* CANNACORD GENUITY: UNDERSTANDING CBD'S TREMENDOUS GROWTH POTENTIAL GLOBAL EQUITIES REPORT SEPTEMBER 2019

FIRST LICENSING DEAL COMPLETE

\$18 BILLION US CBD AND MEDICAL CANNABIS MARKET



Validating both technology and licensing model

- 12 year licensing deal
- Exclusive to the USA
- Columbia Care is a leading player in the US CBD and medical cannabis market
- US CBD market expected to reach US\$18 billion by 2025
- Cost plus double digit royalty rate
- PLUS Double digit profit share depending on distribution channel
- Includes both CBD and medical cannabis applications

14% of Americans say they use CBD products

- 40% for pain
- 20% for anxiety
- 11% for sleep

Gallup June 19-July 12 2019

TECHNOLOGY PLATFORM

COMPELLING PIPELINE OF OPPORTUNITY

- Continuing to grow through development of in house portfolio of branded products
- Execute licensing deals for product in pipeline


GLOBAL MARKETS	TECHNOLOGY	IN MARKET	PIPELINE			
SPORT	Stent	Turbine	CY20	CY21	LICENSING OPPORTUNITIES	
SNORING		Mute				
SLEEP	Airstream Platform	Pronto Sleep	Pronto Sleep Plus - CBD	Pronto Sleep Performance -CBD	Obstructive Sleep Apnea – Medical Cannabis	INSOMNIA
COUGH, COLD CONGESTION		Pronto Clear	Pronto Allergy Relief - CBD		Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)	COPD
NAUSEA			Pronto Nausea Relief - CBD	Pronto Travel - CBD		
PAIN				Pronto Migraine Relief - CBD		MIGRAINE
ANXIETY				Pronto Calm - CBD	Pronto Focus - CBD	PTSD

COMMERCIALISATION STRATEGY

MARKETING PRIMED TO DELIVER REVENUES



- Achieved critical mass of US based retailers – Drug store, Food, mass market
- Strong online presence through Amazon
- Clear year on year ROI (same store sales) on marketing activities established:
 - 12% increase in Promotional investment delivered a 51% increase in Revenues



ESTABLISHING CRITICAL MASS IN KEY MARKETS

PREMIUM RETAIL PARTNERS IN NORTH AMERICA AND ROW

Store Growth



- Presence in 11,000 stores US, 2000 stores ROW
- Premium retail outlets:
 - Online - Amazon USA, UK and Australia
 - Drug Store/Pharmacy – Walgreens/ CVS/ RiteAid (USA), Boots (UK)
- Targeting 30,000+ stores in USA and ROW by 2021
 - Expansion in Drug store/Pharmacy
 - Grocery
 - EDLP + Mass
 - Online – Hong Kong / China



GROW ECOMMERCE REVENUES

ESTABLISHED PRESENCE ON AMAZON, SEEKING TO GROW IN ASIA

- Creating growing presence online through Amazon Australia, Amazon UK and Amazon US
 - Ecommerce already delivering 30% of revenues
- Seeking to drive contribution through new products
- Opportunity to list products online in China and drive revenues from massive Asian market via Alibaba, Tmall, etc.



Rhinomed Turbine Nasal Dilator for Athletic Breathing
 by Rhinomed Limited
 ★★★★★ 208 customer reviews | 23 answered questions
 Amazon's Choice for "turbine nasal dilator"

Available from these sellers.

Style Name: **3 Pack Medium**

3 Pack Assorted from 1 seller	3 Pack Large from 4 sellers	3 Pack Medium from 5 sellers	3 Pack Small from 5 sellers
----------------------------------	--------------------------------	---	--------------------------------

- Pack of 3 Medium Turbine dilators
- 10 Uses per dilator
- Sports breathing technology to increase airflow
- Easy to use, flexible, lightweight
- Trial pack recommended for first time use
- Used by 3-time Tour De France Winner Chris Froome

New (5) from \$21.99

Rhinomed Mute Nasal Dilator for Snoring Reduction
 by Rhinomed Limited
 ★★★★★ 724 customer reviews | 45 answered questions


Was: \$21.48
 With Deal: **\$15.55**
 You Save: **\$5.93 (28%)**

Style Name: **3 Pack Medium**

3 Pack Assorted --	3 Pack Large from 2 sellers	3 Pack Medium \$15.55	3 Pack Small from 2 sellers
-----------------------	--------------------------------	----------------------------------	--------------------------------

- Pack of 3 Medium Mute dilators
- 10 Uses per dilator
- Reduces snoring by gently opening nasal passages
- Easy to use, flexible, lightweight
- Trial pack recommended for first time use

New (5) from \$15.55 Details



LICENSING STRATEGY

PLATFORM APPEAL ACROSS BOTH OTC AND RX APPLICATIONS

- Rhinomed platform provides the potential for a truly unique delivery profile:
 - Fast acting like a spray
 - Sustained release like a patch

Nasal drug delivery offers significant benefits over other delivery modes	Rapid absorption - higher bioavailability
	Fast onset therapeutic mode of action
	Avoidance of first pass through the liver
	Titratable delivery
	Long release
	Controlled/Sustained release
	Ability to micro low dose



LICENSING STRATEGY

CHANGING THE DRUG DELIVERY PARADIGM

1. Rhinomed has established acceptance and adoption of the technology in Global OTC markets as a Class 1 device.
2. Business development program will target those seeking:
 1. An innovative, non-oral, or non-injected delivery platform for their proprietary CNS, systemic, or topical nasal compounds.
 2. To re-evaluate promising compounds that experienced clinical development challenges due to insufficient oral bioavailability, first-pass metabolism, or speed of onset.
 3. To find new or improved uses for existing compounds.



**OUTLOOK AND CAPITAL
RAISING DETAILS**

RHINOMED

KEY CATALYSTS

- 5 new Products to be released before December 2020
 1. Pronto Clear – late 2019
 2. Pronto Sleep Plus - 2020
 3. Pronto Anxiety - 2020
 4. Pronto Nausea - 2020
 5. Pronto Allergy Relief - 2020
- First CBD products to be launched in 2H FY20
 - In US via partner Columbia Care (A\$1.7bn mkt cap) with clinics throughout the USA
 - ROW via existing distribution channels
- Expanding distribution
 - Targeting 30,000+ stores in USA and ROW inside next 2 years
 - Online (Asia)
- Potential Licensing transactions for platform
 - Inbound interest and potential for further transactions
- Quarterly updates on Revenues/Stores
 - Targeting minimum revenue growth of 50% into FY20
 - 2020 product launches underpin significant growth n FY21

CAPITAL RAISING OVERVIEW

- Placement to Sophisticated and Professional investors to raise approximately A\$6.0m via the Company's existing 15% and 10% placement capacity under ASX Listing Rule 7.1 and 7.1A.
- Offer price of \$0.22 represents a:
 - 8.2% discount to 7 day VWAP
 - 17.0% discount to the 30 day VWAP
 - Fund raised will be used to support new product production, significant growth in sales and store rollout

Capital raising timetable

Trading halt	Thursday, 19 th September 2019
Transaction announced & Company resumes trading	Monday, 23 rd September 2019
Settlement of Placement Shares	Thursday 26 th September 2019
Allotment of Placement Shares	Friday, 27 th September 2019



This timetable is indicative only. The company and lead manager reserve the right to update without notification.

APPENDIX A

A NEW APPROACH TO NASAL DRUG DELIVERY

INTRANASAL DRUG ELUTING STENT

- Potential to drive a paradigm shift in drug delivery – combining rapid delivery profile of a spray with long release profile of a patch.
- Three key modalities:
 - Stenting
 - Stenting + Volatile/vapor inhalation delivery
 - Stenting + nasal mucosal delivery
- Strategic appeal to new drug developers, specialty pharma and generic pharma seeking novel delivery solutions



RHINOMED NASAL STENT

IN-SITU NASAL DRUG DELIVERY PLATFORM

A platform delivering stenting, vapour release, drug release, sensor and monitoring capabilities

Two form factors already in market

Independent arm capable of holding medicament formulations, sensors, etc

Proprietary ratcheting stent delivering individualised fit, greater airflow and direct contact with internal nasal dermal and or mucosa surface



Dilates from the back of the nose minimising pressure on the septum and delivering comfort and fit

Manufactured from medical grade polymer (latex and BPA free) capable of releasing medicaments

Mute™ dilation technology providing individual fit and naturally unobstructed breathing



Recharging Pod provides both essential oil recharge and secure storage

Air-Stream™ delivery system places proprietary vapor formulation into nasal air stream without skin contact

Proprietary and pure essential oil blends formulated for optimal effectiveness


Patented Recharging system – recharges in minutes for up to 8 hours of use

GLOBAL PLAY

HIGHLY SCALABLE BUSINESS MODEL

FY19 Mute Revenue contribution	95%
Mute Retail Sales CAGR*	56.6%
Gross Margins	70%
Return on Promotion spend per \$1	\$2.85

- Scale delivered through:
 - Outsourced manufacturing - ChinaMed
 - Existing production capacity able to deliver approx. US\$30m revenues
 - Global logistics network in place
 - Growing retail network – 13,000+stores



* IRI DATE – US Data Store only 52 week period ending April 21 2019

COMPARATORS

GSK + BREATHE RIGHT CASE STUDY



- US based CNS Inc brought Breath Right to market in the mid-90's.
- Over a ten year period Breathe Right pioneered the sleep and snoring category.
- By 2006 the US was responsible for 86% of CNS revenues and Breathe Right was being distributed in 27 countries.
- In 2007 GSK purchased CNS for approximately US\$566m
- The Breathe Right patents expired in 2013.

Rhinomed's Mute product has been in the US for less than 3 years and is now the fastest growing brand in the US drugstore nasal strip category.

Growing at 56% CAGR



Source: <https://www.sawayapartners.com/portfolio/cns/>

APPENDIX B

APPENDIX B INTERNATIONAL OFFER RESTRICTIONS

This document does not constitute an offer of New Shares in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act"). The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

United States

This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

CONTACT

Michael Johnson - CEO

mjohnson@rhinomed.global

